Val Hoyle (D-OR)
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
A Democratic bill with 15 Democratic cosponsors · See all 15 cosponsors
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 requires entities performing federally funded biomedical research to enter into reasonable pricing agreements with the Secretary of Health and Human Services. Under this bill, any biomedical product or service developed with federal research benefits must have a reasonable price as determined by the Secretary (Section 2(a)). Pricing formulas must ensure United States residents are not charged more than the median price in Canada and six other high-income, large-economy countries (Section 2(b)). The Secretary has the authority to create additional requirements to ensure reasonable pricing, including mechanisms to lower prices or shorten exclusivity periods (Section 2(c)). Additionally, the Secretary may waive these obligations if it is in the public interest, following a public notice and economic analysis (Section 2(d)). Finally, companies must report clinical trial costs, government subsidies, and annual revenues by county of sale to the Secretary (Section 2(e)).
Yes· 3 of 10
- Scored +8
Does this lower the price of prescription medicines?
The act mandates reasonable pricing for federally funded biomedical products to reduce costs for residents.
- Scored +7
Would households on low incomes be better off under this?
Lowering prices for healthcare products reduces financial barriers for low-income families.
- Scored +7
Does this make what the government does easier for the public to see?
The bill requires manufacturers to report and make public data regarding costs and revenues.
The opposite
- Scored -4
Would business owners be better off under this?
Pharmaceutical companies and biotech owners may face reduced profit margins under these regulations.
- Scored -3
Does this put more money into medical research?
Mandated pricing agreements could potentially reduce the incentive for private investment in biomedical R&D.
- Scored -2
Does this make patent and copyright rules fairer?
The bill may impact the ease of commercializing intellectual property through mandated pricing and reporting.
Who it would affect, and how
Potential Positive Impacts for People
-
Price Protections for Residents: The bill ensures that United States residents are not charged more for biomedical products or services than the reference price in Canada and six other high-income, large economies (Section 2(b)(1)).
-
Lower Costs and Access: The Secretary can implement requirements designed to lower prices or shorten exclusivity periods when revenues exceed certain targets (Section 2(c)(3)(A)(i)).
-
Reduction of Financial Burdens: The bill allows for mechanisms to lower prices that may otherwise constitute significant barriers to access or fiscal burdens on patients (Section 2(c)(3)(A)(iii)).
-
Increased Transparency: Manufacturers would be required to report the costs of clinical trials, federal subsidies, and annual revenues by county of sale, with these reports being made available to the public (Section 2(e)).
Potential Negative Impacts for People
-
Impact on Research Investment: The Secretary must consider the importance of providing robust incentives to invest in biomedical research and development when creating new pricing requirements (Section 2(c)(2)(B)(i)).
-
Administrative Challenges: The bill notes there may be challenges in administering these agreements, particularly in instances where third parties control necessary intellectual property, know-how, or other assets (Section 2(c)(2)(B)(ii)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Lowering prices for healthcare products reduces financial barriers for low-income families. Would retired people be better off under this? — Reduced medication and medical device costs benefit retirees on fixed incomes. Would middle-income households be better off under this? — Price reductions on biomedical products decrease the overall cost of living and healthcare. Would people with disabilities be better off under this? — More affordable assistive technologies and medical devices benefit people with disabilities. Would people over 65 be better off under this? — Lower drug prices benefit seniors who often rely on biomedical products. Would business owners be better off under this? — Pharmaceutical companies and biotech owners may face reduced profit margins under these regulations.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill requires manufacturers to report and make public data regarding costs and revenues. Does this give the federal government more power? — The bill expands the Secretary of HHS's authority to regulate prices for biomedical products.
- Healthcare
- Does this lower the price of prescription medicines? — The act mandates reasonable pricing for federally funded biomedical products to reduce costs for residents. Does this make health care easier to get in general? — Lowering prices for biomedical services can improve overall healthcare accessibility for the public. Does this put more money into medical research? — Mandated pricing agreements could potentially reduce the incentive for private investment in biomedical R&D.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill enhances consumer protection by capping prices of biomedical products based on international median prices.
- Education And Technology
- Does this make patent and copyright rules fairer? — The bill may impact the ease of commercializing intellectual property through mandated pricing and reporting.
- 10/9/2026
- 1 Cosponsor added.
- 9/1/2026
- 1 Cosponsor added.
- 8/31/2026
- 1 Cosponsor added.
- 8/27/2026
- 1 Cosponsor added.
- 8/20/2026
- 4 Cosponsors added.
- 8/13/2026
- Referred to the House Committee on Energy and Commerce.
- 7 Cosponsors added.
- Introduced in House
Steve CohenDemocrat · Tennessee
Greg CasarDemocrat · Texas
Rosa DeLauroDemocrat · Connecticut
Lloyd DoggettDemocrat · Texas
Jesús GarcíaDemocrat · Illinois
Pramila JayapalDemocrat · Washington
Ro KhannaDemocrat · California
Seth MagazinerDemocrat · Rhode Island
Eleanor NortonDemocrat · District of Columbia
Chellie PingreeDemocrat · Maine
Janice SchakowskyDemocrat · Illinois
Melanie StansburyDemocrat · New Mexico
Mark TakanoDemocrat · California
Rashida TlaibDemocrat · Michigan
Jill TokudaDemocrat · Hawaii